Quick-med Technologies Inc · OTC:QMDT

Quick-med Technologies — Investor Presentation (October 2005)

39 slides from Quick-med Technologies's investor presentation, October 2005

1. Slide 1: 1

   1

2. Slide 2: Company: Overview

   Company: Overview Founded 1997 Headquarters Gainesville, Florida Ticker OTC BB: QMDT Key Technology ƒ MultiStat™ - Anti-aging, anti-inflammatory MMPI ƒ NIMBUS™ - Antimicrobial, absorbent bonded polymer Key Applications Cosmetic, Wound Care, Commercial, Apparel, Personal Care 2

3. Slide 3: Company: Overview

   Company: Overview Board of Directors Michael R. Granito - Chairman David S. Lerner Richard F. Caffrey Lt. Gen. Paul G. Cerjan (Ret.) Maj. Gen. George E. Friel (Ret.) Gerald M. Olderman, Ph.D. Gregory Schultz, Ph.D. Management David S. Lerner - Founder and President Gerald M. Olderman - VP, R&D and C

4. Slide 4: Company: Overview

   Company: Overview Scientific Team Christopher D. Batich, Ph.D. -- Expert in Bio-Medical Engineering and Material Science Gerald M. Olderman, Ph.D. -- Expert in Physical and Surface Chemistry Gregory Schultz, Ph.D. -- Expert in Wound Healing and Skin Chemistry William Toreki, Ph.D.-- Expert in Polyme

5. Slide 5: Core Technologies: MultiStat

   CORE TECHNOLOGIES MultiStat™ 5

6. Slide 6: Core Technology: MULTISTAT

   Core Technology: MULTISTAT™ MultiStat™ A family of Matrix Metalloproteinase inhibitors, or MMPI-related technologies consisting of over 10 patented compounds, patented formulae for developing other compounds, numerous use or method patents and other intellectual property or trade secrets involving t

7. Slide 7: Core Technology: MultiStat

   Core Technology: MultiStat™ MMPI’s When external or internal stimuli trigger an overproduction of certain Matrix Metalloproteinases, or MMPs, chemical reactions within skin cells can cause adverse outcomes such as blistering, inflammation or accelerated collagen degradation. External triggers includ

8. Slide 8: Core Technology: MultiStat (Target Markets)

   Core Technology: MultiStat™ Target Markets Quick-Med Technologies’ current plan is to differentially develop members on the MultiStat™ family for use: 1. As a performance ingredient in cosmetics to reduce the appearance of fine lines and wrinkles that result from aging, reduce redness or have other

9. Slide 9: MultiStat Target Market: Cosmetics

   MULTISTAT™ TARGET MARKET Cosmetics 9

10. Slide 10: Appearance Enhancing Cosmetic Efficacy Evaluation

    Appearance Enhancing Cosmetic Efficacy Evaluation Before After 4 weeks of MultiStat™ use ƒ 4-Week photomicrographic and visual evaluation study conducted by SPF Consulting Labs, Inc. (Pompano Beach, FL) ƒ Evaluators concluded results to be “Exceptional”. ƒ Visual Evaluation: 60% of study participant

11. Slide 11: Core Technology: MultiStat (Partnership - Engelhard)

    Core Technology: MultiStat™ Partnership - Engelhard Corp. • The Partnership between the Company and Engelhard Corporation has defined a broad product development agenda that combines Engelhard’s advanced chemistries and formulation capabilities with MultiStat™ family of MMPI-related technologies. •

12. Slide 12: MultiStat Target Market: Pharmaceutical

    MULTISTAT™ TARGET MARKET Pharmaceutical (Military/Medical) 12

13. Slide 13: Ilomastat Treatment for Mustard Gas and Related Conditions

    Core Technology: MultiStat™ Ilomastat Treatment for Mustard Gas and Related Conditions Research has shown that MMP activity plays a major role in the deterioration of human tissue when exposed to chemical agents such as mustard gas. ƒ Ilomastat, which is a particular member of the MultiStat™ family,

14. Slide 14: Efficacy Experiment: Israel Institute for Biologic Research

    Efficacy Experiment: Israel Institute for Biologic Research No Treatment Ilomastat Treatment Figure 1. Figure 2. Figure 1. Rabbit Eyes Exposed to Mustard Figure 2. Ilomastat significantly reduced Gas. inflammation and neovascularization in rabbit eyes following exposure to mustard gas -- which would

15. Slide 15: Partnership - CRADA

    Core Technology: MultiStat™ Partnership - CRADA On November 15, 2000 -- The Company signed a six-year Cooperative Research and Development Agreement (“CRADA”) with the U.S. Army Medical Research Institute of Chemical Defense to develop a post-injury for eye and skin treatment for mustard gas exposur

16. Slide 16: Core Technology NIMBUS

    CORE TECHNOLOGY NIMBUS™ 16

17. Slide 17: Core Technology - NIMBUS

    Core Technology - NIMBUS™ NIMBUS™ Novel Instrinsically MicroBiocidal Utility Substrate A family of advanced engineered non-toxic polymers Key Properties ƒ Antimicrobial ƒ Superabsorbent ƒ Hemostatic Key Markets ƒ Medical ƒ Consumer ƒ Industrial 17

18. Slide 18: Core Technology - NIMBUS

    Core Technology - NIMBUS™ Technology ƒ A highly active microbicide is covalently bonded to a substrate. ƒ Substrates include cellulosic or wool fibers, webs or fabrics. ƒ A superabsorbent substrate employs the same technology. ƒ The superabsorbent may be dried to a powder which can be formed as a sh

19. Slide 19: Features of the NIMBUS Substrate

    Features of the NIMBUSTM Substrate ƒ The microbicide has a very broad spectrum of activity. ƒ High surface charge density enables the high performance. ƒ Because NIMBUS™ works by the process of cell disruption, bacterial resistance is unlikely.* ƒ Loss of efficacy in the presence of proteins from fo

20. Slide 20: Mechanism Of Bacterial Cell Disruption by NIMBUS

    Mechanism Of Bacterial Cell Disruption by NIMBUSTM E. Coli Drains and Collapses After Contact with a Quat. Before After Cell Contents Bacterial Cell (-) (-) Polymer Chain Substrate + + + + + Cell Wall + + + + (-) Covalent Bond (-) (-) Membrane 20 Antimicrobial Techniques for Medical Nonwovens by C W

21. Slide 21: Core Technology - NIMBUS

    Core Technology - NIMBUS™ Benefits ƒ Highly effective against pathogenic bacteria. ƒ Virucidal and fungicidal. ƒ Rapid absorbency, high absorbent capacity. ƒ Launderable. ƒ Eliminates bacteria that cause food/body odors. ƒ Eliminates fungi that cause athlete’s foot and mildew. ƒ Hemostatic. 21

22. Slide 22: Benefits of the NIMBUS Substrate

    Benefits of the NIMBUSTM Substrate • Highly effective against pathogenic bacteria • Virucidal and fungicidal • Quick and prolonged action • Rapid absorbency, high absorbent capacity • Launderable • Eliminates bacteria that cause food and body odors • Eliminates fungi that cause athlete’s foot and mi

23. Slide 23: Core Technology - NIMBUS

    Core Technology - NIMBUS™ Various Forms ƒ Substrate - fabric, paper, fiber, yarn or composite. ƒ Dispersible particle - mica, starch, clay, silica, TiO2. ƒ Dispersible polystyrene microspheres. ƒSuperabsorbent polymer - powder, gel, dry sheet. ƒ Delivery vehicle with a second active agent: MultiStat

24. Slide 24: Applications of NIMBUS Materials

    Applications of NIMBUSTM Materials POTENTIAL MARKE TS FOR NIMBUSŖ Medic al Produ cts Consumer Products Industrial Products » Cosmetic » Insulation moldicide » Anti-bacterial wound dressing » Personal care » Hospitality industry » Hemostatic bandage - life » Feminine care » Fiber glass insulation thr

25. Slide 25: NIMBUS Test Results

    NIMBUSTM Test Results • Broad spectrum microbicidal efficacy • Problem bacteria in various applications • Bacterial kill rates • Duration of action • Twice inoculated effectiveness • Zone of inhibition • Leachability • Launderability • Rate of delivery/stabilization of anions • Wood preservation • C

26. Slide 26: Broad Spectrum Microbicidal Efficacy

    Broad Spectrum Microbicidal Efficacy* Kill levels for: Percent killed Staphylococcus aureus > 99.9999% Eschericia coli > 99.9999% Klebsiella pneumoniae > 99.9999% Pseudomonas aeruginosa > 99.9999% Proteus vulgaris > 99.9999% Serratia marcescens > 99.9999% Enterococcus faecalis > 99.9999% Enterobacte

27. Slide 27: Fabric/Personal Care: NIMBUS Kills Problem Bacteria

    Fabric/Personal Care: NIMBUS™ Kills Problem Bacteria Problem to Bacteria or Fungus NIMBUSTM Correct Efficacy Urine Odor ƒProteus vulgaris 99.999% ƒPseudomonas aeruginosa 99.999% ƒMicrococcus luteus 99.940% Perspiration Odor ƒStaphylococcus epidermidis 99.999% ƒPropionibacterium acne 99.999% ƒCoryneb

28. Slide 28: High kill rate starts in minutes and lasts for at least 12 hours

    High kill rate starts in minutes* and lasts for at least 12 hours PERCENTAGE KILLED KILLED WITHIN INDICATED TIME Time (min.) Staph. a. E. Coli * Tested in 1 99.82 % 96.43% 10% bovine serum 10 99.95% 99.98% 20 99.95% 99.99% 30 99.993% 99.998% 60 99.992% 99.998% 4 hours 99.998% 99.9999% 8 hours 99.999

29. Slide 29: Prolonged Microbicidal Effect

    Prolonged Microbicidal Effect Duration of Microbicidal Efficacy in the Presence of 10% Bovine Serum Sample Staph. aureus (cfu/ml.) E. coli. (cfu/ml.) 18 hour control 3.8 x106 1.2 x106 18 hour QMT sample <3 <3 3 day control 4.3x106 6.0 x106 3 day QMT sample <3 <3 7 day control 6.5 x106 3.7 x106 7 day

30. Slide 30: Repeated Inoculation Test Results

    Repeated Inoculation Test Results (1) Sample Staph. Aureus E. Coli Control 4.1 x108 3.2x108 DC 5700 1.6 x 106 2.2x108 (Aegis Bioshield) NIMBUSTM 1.7 x 102 2.7x102 The results indicate that NIMBUSTM kills all but one in a million bacteria per ml. NIMBUSTM is more effective in eliminating over a billi

31. Slide 31: Zone of Inhibition: No Effect of Active Agent Beyond the Substrate

    Zone of Inhibition No Effect of Active Agent Beyond the Substrate Effect of Gauze Extract on Bacterial Growth SAMPLE STAPHYLOCOCCUS ESCHERICHIA AUREUS COLI Control No Inhibition No Inhibition NIMBUS™ No Inhibition No Inhibition ƒ Antimicrobial release test of gauze after soaking in PBS for 4 hours 3

32. Slide 32: Zone of Inhibition Control: Gauze Sponges With No Microbicide

    Zone of Inhibition Control: Gauze Sponges With No Microbicide Samples were inoculated with various volumes of 5.8 x 10E3 cfu/mL of E. coli in PBS (counter-clockwise from top right: 0.5 mL, 0.75 mL, 2.0 mL, and 1.25 mL), and then incubated for 15 hours at 37 degrees C tryptic soy agar (Difco) contain

33. Slide 33: Zone of Inhibition: Gauze Sponges With NIMBUS

    Zone of Inhibition: Gauze Sponges With NIMBUSTM Samples were inoculated with various volumes of 5.8 x 10E3 cfu/mL of E. coli in PBS (counter-clockwise from top right: 0.5 mL, 0.75 mL, 2.0 mL, and 1.25 mL), and then incubated for 15 hours at 37 degrees C tryptic soy agar (Difco) containing 0.01% TTC.

34. Slide 34: What Does Having No Zone Of Inhibition Mean?

    What Does Having No Zone Of Inhibition Mean? ƒ The microbicide is bonded. ƒ Does not migrate from the substrate. ƒ Continuous action isn’t depleted. ƒ Launderable without loss of efficacy. ƒ NIMBUSTM is a device not a drug. 34

35. Slide 35: Leachability: Agent Is Not Extractable

    Leachability: Agent Is Not Extractable Effect of Gauze Eluant on Bacterial Growth SAMPLE STAPHYLOCOCCUS ESCHERICHIA AUREUS COLI Control No Inhibition No Inhibition NIMBUS™ No Inhibition No Inhibition ƒ Antimicrobial release after 42 hours on a rotary shaker. 35

36. Slide 36: Launderability: NIMBUS vs. AEGIS Microbe Shield

    LAUNDERABILITY(1) NIMBUSTM vs. AEGIS Microbe ShieldTM Sample Staph. Aureus E. Coli UNTREATED 4.4 x 105 2.7 x105 CONTROL NIMBUSTM - 5x < 2.0 = 99.9995% < 2.0 = 99.9995% NIMBUSTM - 25x < 2.0 = 99.9995% 270 = 99.90% AEGIS microbicide - 5x) 2.1 x 106 = Growth 5.6 x 106 = Growth Note: (1) Laundered at th

37. Slide 37: Delivery of Anionic MMPI: NIMBUS vs. Rayon Control

    Delivery of Anionic MMPI NIMBUS™ vs. Rayon Control Extraction of Ilomastat 0.16 0.14 0.12 0.1 NIMBUS 0.08 0.06 Rayon 0.04 0.02 0 1 2 3 4 5 6 7 8 9 10 11 12 Extraction cycle (10 mL each) 37

38. Slide 38: Summary

    SUMMARY ƒ NIMBUSTM offers a number of performance features and benefits suitable for use in a broad range products. ƒ NIMBUSTM can be produced in various forms allowing its incorporation into many different product types. ƒ MULTISTATTM offers further innovative product opportunities. 38

39. Slide 39: Contact Information

    Contact Information Quick-Med Technologies, Inc. Business Development, Please Contact: David Lerner - President Tel: 561.750.4202 Research & Development, Please Contact: Gerald M. Olderman - VP, Research & Development Tel: 781.271.9893 Investor Relations, Please Contact: Natasha A. Sorobey - Corpora

Quick-Med Technologies — Investor Presentation (October 2005) on 6ix